Kazia Therapeutics - Reinvestment period with increased R&D focus
Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical...
222 Views
Kazia Therapeutics - Collaboration may expand utility to combo therapies
Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research...
675 Views
Kazia Therapeutics - EVT801 data published in peer-reviewed journal
Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research...
681 Views
Kazia Therapeutics - Q123 cash flows in line with our estimates
Kazia Therapeutics’ Q123 cash flow report provided an update on the company’s financial position and business progress. While the quarter was...
393 Views
Kazia Therapeutics - PNOC022 trial expanded
Kazia Therapeutics has announced the expansion of the PNOC022 (NCT05009992) trial to two new sites in Australia. The Phase II trial is...
676 Views